期刊文献+

药物基因组学在新药临床研究中的应用现状 被引量:7

Application status of pharmacogenomics in clinical researches of new drugs
原文传递
导出
摘要 药物基因组学(PGx)主要研究基因多态性等遗传特性对药物代谢、药效和药物不良反应的影响,旨在为新药研发、临床试验、注册上市、个体化药物治疗提供科学依据。随着制药行业的蓬勃发展,药物基因组学已经在新药研发和上市药品再评价的临床研究中获得越来越多的应用。药物基因组学可以大大缩短药物开发周期,降低新药研究成本,有助于优化药品的临床应用方案,提高药物临床应用的安全性和有效性。本文针对药物基因组学在临床研究各阶段中的具体应用及其发展展望等内容进行综述。 Pharmacogenomics( PGx) mainly studies the influence of gene polymorphisms and other genetic characteristics on drug metabolism,efficacy and adverse drug reactions,and aims to provide scientific basis for new drug research and development,clinical trials,registration,and indivi-dualized drug therapy. With the vigorous development of the pharmaceutical industry,PGx has been more and more applied not only in the research and development of new drugs but also in drug post-marketed re-evaluation. PGx can greatly shorten the drug development cycle,reduce the cost of new drug research,and help to optimize the clinical application of drug therapy to improve safety and efficacy. This paper reviews on the specific application of PGx in various stages of clinical research and its developmental prospect.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2017年第23期2508-2510,共3页 The Chinese Journal of Clinical Pharmacology
关键词 药物基因组学 新药研发 临床研究 临床试验 pharmacogenomics new drug research and development clinical research clinical trial
  • 相关文献

参考文献4

二级参考文献23

  • 1胡祥鹏,许建明,胡咏梅,梅俏,徐新华,徐叔云.CYP2C19基因多态性对奥美拉唑在中国人体内的药物动力学和药效学的影响[J].中国药理学通报,2005,21(10):1210-1213. 被引量:28
  • 2Dubinsky M C,Gastroenterology,2000年,118卷,705页
  • 3Shi M M,Mol Diagn,1999年,4卷,343页
  • 4Hancox R J,Eur Respei J,1998年,11卷,589页
  • 5US Food and Drug Administration. Guidance for industry pharma-cogenomic data submissions [ EB/OL ]. http ://www. fda. gov/ downloads/RegulatoryInformation/Guidances/ucm126957, pdf, 2005 - 03 - 22.
  • 6European Medicines Agency. Guideline on the use of pharmacoge- netic methodologies in the pharmacokinetic evalution of medicinal products[EB/OL], http://www, ema. europa, eu/docs/en_GB/ document _ library/Scientific _ guideline/2012/O2/WC500121954. pdf,2012 -01 - 19.
  • 7Watanabe I, Tomita A, Shimizu M, et al. A study to survey s - us- ceptible genetic factors responsible for troglitazone -associated hep- atotoxicityin Japanese patients with type 2 diabetes mellitus [ J ]. Clin Pharmacol Ther,2003 ,73 :436 - 455.
  • 8Yoo HD, Kim MS, Cho HY, et al. Population pharmacokinetic a- nalysis of glimepirid with CYP2C9 genetic polymorphism in healthy Korean subjects [ J ]. Eur J Clin Pharmacol,2011,67:889 - 898.
  • 9Zou JJ,Ding L,Tan J. CYP2C19 681G >A polymorphism and phar- macokinetics of clopidogrel in Chinese healthy volunteers [ J ]. Pharmazie,2012,67 : 795 - 797.
  • 10Hagymtsi K, Mtlllner K, Hcrsz6nyi L,et al. Update on the pharma- cogenomics of proton pump inhibitors [ J ]. Pharmacogenomics, 2011,12:873 - 888.

共引文献31

同被引文献53

引证文献7

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部